Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 572,834 shares of the company's stock after acquiring an additional 61,114 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.75% of Nurix Therapeutics worth $10,792,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of NRIX. US Bancorp DE increased its stake in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after acquiring an additional 842 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Nurix Therapeutics in the fourth quarter valued at approximately $376,000. Bank of New York Mellon Corp raised its position in Nurix Therapeutics by 8.9% in the fourth quarter. Bank of New York Mellon Corp now owns 190,905 shares of the company's stock valued at $3,597,000 after purchasing an additional 15,639 shares during the period. Rhumbline Advisers lifted its stake in shares of Nurix Therapeutics by 13.5% in the 4th quarter. Rhumbline Advisers now owns 103,233 shares of the company's stock valued at $1,945,000 after purchasing an additional 12,315 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Nurix Therapeutics by 42.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after purchasing an additional 235,971 shares during the period.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. BTIG Research started coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They issued a "buy" rating and a $35.00 price objective on the stock. BMO Capital Markets initiated coverage on Nurix Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $35.00 price objective for the company. Royal Bank of Canada increased their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. dropped their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Finally, Needham & Company LLC cut their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $30.88.

Nurix Therapeutics Price Performance

NRIX traded up $0.15 during trading on Wednesday, reaching $12.73. 812,197 shares of the stock were exchanged, compared to its average volume of 871,639. Nurix Therapeutics, Inc. has a 1 year low of $11.90 and a 1 year high of $29.56. The company has a market capitalization of $966.04 million, a price-to-earnings ratio of -4.40 and a beta of 2.18. The business's 50 day moving average price is $16.76 and its two-hundred day moving average price is $20.59.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. This represents a 14.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is owned by insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.